We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01904409
Recruitment Status : Completed
First Posted : July 22, 2013
Last Update Posted : March 3, 2016
Information provided by (Responsible Party):
Valeant Pharmaceuticals International, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : June 2015
  Study Completion Date : July 2015